CLINICAL AND LABORATORY STANDARDS INSTITUTE®

4th Edition

# M27

# Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts

This standard covers antifungal agent selection and preparation, test procedure implementation and interpretation, and quality control requirements for susceptibility testing of yeasts that cause invasive fungal infections.

A standard for global application developed through the Clinical and Laboratory Standards Institute consensus process.

# Clinical and Laboratory Standards Institute

*Setting the standard for quality in medical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

**Consensus Process**

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

**Commenting on Documents**

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

**Appeal Process**

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the CLSI *Standards Development Policies and Processes,* is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

**Get Involved—Volunteer!**

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute
950 West Valley Road, Suite 2500
Wayne, PA 19087 USA
P: +1.610.688.0100
F: +1.610.688.0700
www.clsi.org
standard@clsi.org

M27, 4th ed.
November 2017
Replaces M27-A3

# Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts

Barbara D. Alexander, MD, MHS
Gary W. Procop, MD, MS
Philippe Dufresne, PhD (RMCCM)
Jeff Fuller, PhD, FCCM, D(ABMM)
Mahmoud A. Ghannoum, PhD, EMBA, FIDSA
Kimberly E. Hanson, MD, MHS
Denise Holliday, MT(ASCP)
Nicole M. Holliday, BA
Laura Kovanda, PhD
Shawn R. Lockhart, PhD, D(ABMM)
Luis Ostrosky-Zeichner, MD, FACP, FIDSA, FSHEA
Audrey N. Schuetz, MD, MPH, D(ABMM)
Nathan P. Wiederhold, PharmD
Adrian M. Zelazny, PhD, D(ABMM)

## Abstract

Clinical and Laboratory Standards Institute standard M27—*Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts* describes a method for testing the susceptibility to antifungal agents of yeasts that cause invasive fungal infections, including *Candida* spp. and *Cryptococcus neoformans.* Selection and preparation of antifungal agents, implementation and interpretation of test procedures, and the purpose and implementation of QC procedures are discussed. A careful examination of the responsibilities of the manufacturer and the user in QC is also presented.

Clinical and Laboratory Standards Institute (CLSI). *Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts.* 4th ed. CLSI standard M27 (ISBN 1-56238-826-6 [Print]; ISBN 1-56238-827-4 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2017.



## Suggested Citation

CLSI. *Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts.* 4th ed. CLSI standard M27. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.

**Previous Editions:**
December 1992, October 1995, June 1997, August 2002, April 2008

ISBN 1-56238-826-6 (Print)
ISBN 1-56238-827-4 (Electronic)
ISSN 1558-6502 (Print)
ISSN 2162-2914 (Electronic) Volume 37, Number 13

# Committee Membership

## Consensus Council

**Carl D. Mottram, RRT, RPFT, FAARC**
**Chairholder**
**Mayo Clinic**
**USA**

**Dennis J. Ernst, MT(ASCP), NCPT(NCCT)**
**Vice-Chairholder**
**Center for Phlebotomy Education**
**USA**

J. Rex Astles, PhD, FACB, DABCC
Centers for Disease Control and Prevention
USA

Lucia M. Berte, MA, MT(ASCP)SBB, DLM, CQA(ASQ)CMQ/OE
Laboratories Made Better!
USA

Karen W. Dyer, MT(ASCP), DLM
Centers for Medicare & Medicaid Services
USA

Thomas R. Fritsche, MD, PhD, FCAP, FIDSA
Marshfield Clinic
USA

Mary Lou Gantzer, PhD, FACB
BioCore Diagnostics
USA

Loralie J. Langman, PhD, DABCC, FACB, F-ABFT
Mayo Clinic
USA

Ross J. Molinaro, PhD, MLS(ASCP)CM, DABCC, FACB
Siemens Healthcare Diagnostics, Inc.
USA

Joseph Passarelli
Roche Diagnostics Corporation
USA

Andrew Quintenz
Bio-Rad Laboratories, Inc.
USA

Robert Rej, PhD
New York State Department of Health – Wadsworth Center
USA

Zivana Tezak, PhD
FDA Center for Devices and Radiological Health
USA

## Subcommittee on Antifungal Susceptibility Tests

**Barbara D. Alexander, MD, MHS**
**Chairholder**
**Duke Univeristy Medical Center**
**USA**

**Gary W. Procop, MD, MS**
**Vice-Chairholder**
**Cleveland Clinic**
**USA**

Philippe Dufresne, PhD (RMCCM)
Institut national de santé publique du Québec
Canada

Jeff Fuller, PhD, FCCM, D(ABMM)
London Health Sciences Centre
Canada

Mahmoud A. Ghannoum, PhD, EMBA, FIDSA
Case Western Reserve University
USA

Kimberly E. Hanson, MD, MHS
University of Utah and ARUP Laboratories
USA

Denise Holliday, MT(ASCP)
BD Diagnostic Systems
USA

Nicole M. Holliday, BA
Thermo Fisher Scientific
USA

Luis Ostrosky-Zeichner, MD, FACP, FIDSA, FSHEA
Memorial Hermann Healthcare System
USA

Audrey N. Schuetz, MD, MPH, D(ABMM)
Mayo Clinic
USA

Nathan P. Wiederhold, PharmD
University of Texas Health Science Center at San Antonio
USA

Adrian M. Zelazny, PhD, D(ABMM)
USA

**Staff**

Clinical and Laboratory Standards Institute
USA

Marcy L. Hackenbrack, MCM, M(ASCP)
*Project Manager*

Megan L. Tertel, MA, ELS
*Editorial Manager*

Catherine E.M. Jenkins
*Editor*

Kristy L. Leirer, MS
*Editor*

Laura Martin
*Editor*

**Acknowledgment for the Expert Panel on Microbiology**

CLSI, the Consensus Council, and the Subcommittee on Antifungal Susceptibility Tests gratefully acknowledge the Expert Panel on Microbiology for serving as technical advisors and subject matter experts during the development of this standard.

**Expert Panel on Microbiology**

**Richard B. Thomson, Jr., PhD, D(ABMM), FAAM**
**Chairholder**
**Evanston Hospital, NorthShore University HealthSystem**
**USA**

**Mary Jane Ferraro, PhD, MPH**
**Vice-Chairholder**
**Massachusetts General Hospital**
**USA**

Lynette Y. Berkeley, PhD, MT(ASCP)
FDA Center for Drug Evaluation and Research
USA

Carey-Ann Burnham, PhD, D(ABMM)
Washington University School of Medicine
USA

German Esparza, BSc
Proasecal LTD
Colombia

Mark G. Papich, DVM, MS
College of Veterinary Medicine, North Carolina State University
USA

Jean B. Patel, PhD, D(ABMM)
Centers for Disease Control and Prevention
USA

David H. Pincus, MS, RM/SM(NRCM), SM(ASCP)
bioMérieux, Inc.
USA

Audrey N. Schuetz, MD, MPH, D(ABMM)
Mayo Clinic
USA

Ribhi M. Shawar, PhD, D(ABMM)
FDA Center for Devices and Radiological Health
USA

Barbara L. Zimmer, PhD
Beckman Coulter - West Sacramento
USA

**Acknowledgment**

CLSI, the Consensus Council, and the Subcommittee on Antifungal Susceptibility Tests gratefully acknowledge the following volunteers for their important contributions to the development of this standard:

Laura Kovanda, PhD
Astellas Pharma
USA

Shawn R. Lockart, PhD, D(ABMM)
Centers for Disease Control and Prevention
USA

**Acknowledgment**

CLSI, the Consensus Council, and the Subcommittee on Antifungal Susceptibility Tests gratefully acknowledge the following former subcommittee members for their review of this standard during development:

Sharon K. Cullen, BS, PMP, RAC
Beckman Coulter - West Sacramento
USA

Shawn R. Lockhart, PhD, D(ABMM)
Centers for Disease Control and Prevention
USA

David S. Perlin, PhD
New Jersey Medical School-UMDNJ
USA

Dee Shortridge, PhD
JMI Laboratories
USA

Nancy L. Wengenack, PhD, D(ABMM)
Mayo Clinic
USA

## Contents

Abstract ..... i

Committee Membership ..... iii

Foreword ..... vii

Chapter 1: Introduction ..... 1

1.1 Scope ..... 1
1.2 Background ..... 1
1.3 Standard Precautions ..... 2
1.4 Terminology ..... 2

Chapter 2: Preparing for Antifungal Susceptibility Testing ..... 5

2.1 Indications for Performing Antifungal Susceptibility Tests ..... 5
2.2 Selecting Antifungal Agents for Routine Testing and Reporting ..... 6

Chapter 3: Antifungal Broth Dilution Susceptibility Testing Process for Yeasts ..... 7

3.1 Preparing Antifungal Agents ..... 9
3.2 Testing Procedures ..... 11
3.3 Reading Minimal Inhibitory Concentration Results ..... 15
3.4 Interpreting Results ..... 17

Chapter 4: Quality System Essential: Process Management – Quality Control ..... 19

4.1 Quality Control Purpose ..... 19
4.2 Quality Control Responsibilities ..... 19
4.3 Selecting Reference Strains ..... 20
4.4 Storing Reference Strains ..... 20
4.5 Controlling Media Batches and Plasticware Lots ..... 22
4.6 Quality Control Frequency ..... 22
4.7 Other Quality Control Procedures ..... 23

Chapter 5: Conclusion ..... 24

Chapter 6: Supplemental Information ..... 24

References ..... 25

Appendix A. Preparing Dilution Series of Water-Insoluble Antifungal Agents to Be Used in Broth Dilution Susceptibility Tests ..... 27

Appendix B. Composition of Roswell Park Memorial Institute 1640 Culture Medium (With Glutamine and Phenol Red but Without Bicarbonate) ..... 28

Appendix C. Preparing Roswell Park Memorial Institute 1640 Culture Medium ..... 29

Appendix D. Preparing Dilution Series of Water-Soluble Antifungal Agents to Be Used in Broth Dilution Susceptibility Tests ..... 30

Appendix E. 0.5 McFarland Barium Sulfate Turbidity Standard ..... 31

The Quality Management System Approach ..... 32

Related CLSI Reference Materials ..... 33

## Foreword

With the increased incidence of systemic fungal infections and the growing number of available antifungal agents, laboratory guidance for selecting antifungal therapy has gained greater attention. In 1982, the CLSI Area Committee for Microbiology formed the Subcommittee on Antifungal Susceptibility Tests. In 1985, this subcommittee published its first report, in which the results of a questionnaire and a small collaborative study were presented. Based on these findings, the subcommittee concluded that it would be useful to work toward a more reproducible reference testing procedure.

Agreement already existed regarding several elements of the procedure. For example, to facilitate additional analysis of various test conditions, it was agreed that the reference method should be a broth dilution procedure. Because of examples of drug antagonism by some complex media for certain antifungal agents, the subcommittee restricted its interest to fully defined synthetic media only. Drug stock solution preparation and dilution procedures previously developed for antibacterial testing procedures were adopted with minor modifications. Despite agreement in some areas, for other factors, additional data needed to be resolved, including:

- Inoculum preparation
- Inoculum size
- Choice among several synthetic media
- Incubation temperature
- Incubation duration
- End-point definition

These factors were the focus of a series of collaborative studies.[1-4] As a result, the subcommittee reached agreement on all factors, which led to the publication of M27-P in 1992. In the next four years, reference minimal inhibitory concentration (MIC) ranges were established for two QC strains for the available antifungal agents,[5,6] and broth microdilution procedures paralleling the broth macrodilution reference procedure became available.[4,7-9] This information was included in a revised standard in 1995 (M27-T). In revising the standard, the subcommittee focused its attention on developing relevant breakpoints for available antifungal agents,[10] included in M27-A in 1997. Since then, the subcommittee has developed 24- and 48-hour reference MIC ranges for microdilution testing of both established and newly introduced antifungal agents.[11] The study results are included in this standard and CLSI document M60.[12]

## Overview of Changes

This standard replaces the previous edition of the approved standard, M27-A3, published in 2008. Several changes were made in this edition, including:

- **General:**
  - Revised document format and organization to reflect the CLSI quality system essential and path of workflow document templates and the updated CLSI style
  - Updated references to the previous informational supplements (M27-S4 and M44-S3) to reflect CLSI document M60,[12] the new supplement for broth dilution and disk diffusion yeast susceptibility testing
  - Added references to epidemiological cutoff values and CLSI documents M57[13] and M59[14]

M27, 4th ed.

- **Subchapter 1.4.2, Definitions:**
  - Revised the breakpoint and interpretive category definitions for consistency with other CLSI antimicrobial susceptibility testing documents
  - Added definitions for “wild-type” and “non-wild-type”
  - Deleted all uses of the phrase “interpretive criteria”
- **Chapter 3, Antifungal Susceptibility Testing Process:**
  - Added an antifungal susceptibility testing process flow chart
  - Replaced procedural text with step-action tables
  - Added an explanation for deleting breakpoints for itraconazole and flucytosine
  - Changed recommended reading time for broth microdilution to 24 hours only for clinical isolates and QC strains (24 and/or 48 hours was accepted for some antifungal agents in M27-A3)
  - Deleted results interpretation information for ketoconazole

**NOTE:** The content of this standard is supported by the CLSI consensus process and does not necessarily reflect the views of any single individual or organization.

**Key Words**

Antifungal agent, broth macrodilution, broth microdilution, susceptibility testing, yeasts

# Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts

## Chapter 1: Introduction

This chapter includes:

- Standard's scope and applicable exclusions
- Background information pertinent to the standard's content
- Standard precautions information
- "Note on Terminology" that highlights particular use and/or variation in use of terms and/or definitions
- Terms and definitions used in the standard
- Abbreviations and acronyms used in the standard

### 1.1 Scope

This standard describes a reference method for testing susceptibility to antifungal agents of yeasts that cause infections, including *Candida* spp. and *Cryptococcus* spp. The intended users are laboratory personnel who perform antifungal susceptibility testing on yeasts. The focus is on developing relevant breakpoints for available antifungal agents[10] and reference minimal inhibitory concentration (MIC) ranges for broth dilution testing of both established and newly introduced antifungal agents.[11] For MIC breakpoints, interpretive categories, and MIC ranges for QC isolates, refer to CLSI document M60.[12]

This method has not been extensively validated for the yeast forms of dimorphic fungi, such as *Blastomyces dermatitidis* or *Histoplasma capsulatum.* Also, testing filamentous fungi (moulds) introduces several additional standardization problems not covered by this procedure and is not included. For an antifungal broth dilution susceptibility testing reference method for filamentous fungi, refer to CLSI document M38.[15]

Commercially available susceptibility test systems are out of scope for this standard. It is recommended that users of these systems refer to the manufacturer's instructions as outlined in the package insert.

### 1.2 Background

This standard provides a reference method developed through a consensus process to facilitate agreement among laboratories in measuring yeast susceptibility to antifungal agents. An important use of a reference method is to provide a standard basis from which other methods can be developed, which also results in interlaboratory agreement within specified ranges. For example, broth microdilution methods using an indicator dye to facilitate breakpoint determinations have been configured to produce results paralleling those obtained by the broth microdilution reference method. To the extent that any method produces results concordant with this reference method, it would be considered to conform with this standard.